• Company News
  • Food for Thought
  • Calendar & Events
  • Business Life

    • Company News: Micromet Presents Updated Results From Phase 1 and Phase 2 Study of Blinatumomab


    Monday, June 14, 2010

    - Update Presented at the 15th Annual Congress of the European Hematology Association (EHA) -

    Micromet, Inc. (NASDAQ: MITI) today announced updated clinical data from a Phase 1 and a Phase 2 trial, respectively, of its lead product blinatumomab (MT103). The data were presented at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.  ยป Read more...

    By akampion Posted in Company News No Comments